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Abstract
Congenital myopathies are genetically and clinically heterogeneous conditions causing severe muscle weakness, and
mutations in the ryanodine receptor gene (RYR1) represent themost frequent cause of these conditions. A common feature of
diseases caused by recessive RYR1mutations is a decrease of ryanodine receptor 1 protein content in muscle. The aim of the
present investigation was to gain mechanistic insight into the causes of this reduced ryanodine receptor 1. We found that
muscle biopsies of patients with recessive RYR1 mutations exhibit decreased expression of muscle-speciﬁc microRNAs,
increased DNAmethylation and increased expression of class II histone deacetylases. Transgenic mousemuscle ﬁbres over-
expressing HDAC-4/HDAC-5 exhibited decreased expression of RYR1 and of muscle-speciﬁc miRNAs, whereas acute knock-
down of RYR1 in mouse muscle ﬁbres by siRNA caused up-regulation of HDAC-4/HDAC-5. Intriguingly, increased class II
HDAC expression and decreased ryanodine receptor protein and miRNAs expression were also observed in muscles of
patients with nemaline myopathy, another congenital neuromuscular disorder. Our results indicate that a common
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pathophysiological pathway caused by epigenetic changes is activated in some forms of congenital neuromuscular
disorders.
Introduction
Congenital myopathies constitute a genetically and phenotypic-
ally broad spectrum of disorders characterized clinically bymus-
cle weakness and atrophy, joint contractures, spinal deformities
and variable cardiorespiratory involvement. Congenital myop-
athies have been historically deﬁned by their most predominant
histopathological feature, with major entities being central core
disease (CCD), multi-minicore disease (MmD), nemaline myop-
athy (NM) and congenital ﬁbre type disproportion (CFTD) (1–4).
Their severe complications require patients to receive continual
medical attention, resulting in a substantial individual, familial,
and social disease burden. Each congenital myopathy can be
caused by mutations in more than one gene, and mutations in
the same gene can cause different pathological phenotypes.
The prime examples are ryanodine receptor 1 (RYR1)-relatedmy-
opathies, caused bymutations in the gene encoding the RyR1, the
calcium release channel of the skeletal muscle sarcoplasmic re-
ticulum. Physiologically, activation of the RyR1 leads to release
of calcium from the sarcoplasmic reticulum, leading to muscle
contraction by a process called excitation–contraction coupling
(ECC) (5). Excitation–contraction coupling occurs at the triad, a
structure made up of two membrane compartments: the trans-
verse tubules containing the voltage-gated dihydropyridine re-
ceptors and the sarcoplasmic reticulum terminal cisternae
containing the RyR1. ECC requires the proper distribution and
assembly of sarcoplasmic reticulum proteins, and tight regula-
tion of calcium homeostasis is critical for proper muscle func-
tion. Indeed, mutations in RYR1 lead to calcium dysregulation
and are the underlying cause of several neuromuscular disor-
ders. While most dominant mutations associated with CCD and
malignant hyperthermia susceptibility are missense (6), reces-
sive mutations associated with the pathological phenotypes of
MmD, centronuclear myopathy (CNM) and CFTD (1–4) are often
compound heterozygous, with one allele presenting a non-
sense, intronic splice site or a frameshift mutation, and the
other allele presenting a missense mutation (3,4). As to their
mode of action, dominant missense mutations affect the bio-
physical properties of the RyR Ca2+ channel (6), whereas for reces-
sivemutations, themechanism is still elusive, though a common
ﬁnding is the low levels of RyR1 and of other SR proteins in biop-
sied muscles (2–4,7). Intriguingly, this decrease occurs only in
mature muscle and not in other tissues expressing RyR1 such
as B-lymphocytes (8).
Because of their heterogeneity, one of the major aims of
research in congenital myopathies is to ﬁnd a common target
in order to develop a pharmacological tool to help improve
muscle function and thus quality of life in this group of pa-
tients. In fact, though the number of patients with a given gen-
etic form of a disease is small (1:3000), the number of patients
suffering from inheritable congenital myopathies worldwide is
∼286 million (9) with CCD accounting for 16% of cases, nema-
line rod myopathy for 20%, CNM for 14% and multicore myop-
athy for 10% (http://www.muscular-dystrophy.org/research/
patient_registries) (1). Thus, discovering a common target
downstream of the primary genetic defect could potentially
beneﬁt a large number of patients. The ﬁndings of the present
investigation indicate that common epigenetic changes conse-
quent to the primary genetic defect are activated in different
congenital myopathies.
Results
Calcium homeostasis in myotubes from patients
with mutations leading to decrease RyR1 content
Our ﬁrst approachwas to study calciumhomeostasis inmyotubes
derived frombiopsies of four patients initially diagnosed ashaving
MmD, three of whomcarry recessive RYR1mutations and one car-
rying the heterozygous mutation p.G297D but who exhibited re-
duced RyR1 protein on western blot. Subsequent whole-exome
sequencing later revealed that the patient also harboured two
compound heterozygous NEB mutations and is therefore identi-
ﬁed as NEM UK06 in Figure 1. Figure 1 shows that the resting
fura-2 ﬂuorescence ratio (340/380 nm) as well as the KCl-depend-
ent calcium release curves were not different, except for patient
Minicore UK 07, who showed a signiﬁcantly reduced sensitivity
to KCl (EC50 for KCl was 55.3 ± 8.2 in myotubes from Minicore
UK07 compared with 13.9 ± 8.4 in myotubes from controls)
(Fig. 1A and B). The KCl-dependent calcium release curve for pa-
tient Minicore UK08 (dotted trace with asterisk symbol Fig. 1B)
had also been previously reported to be similar to that of control
myotubes (10). These results were surprising as western blots of
muscle biopsies from all four patients showed a very large reduc-
tion of RyR1 protein content (Fig. 1C) leading us to expect a large
effect on calciumhomeostasis inmyotubes. Because of these rea-
sons, we hypothesized that the mechanism leading to reduced
RyR1 expression is only operative in more mature tissues, such
asmyoﬁbres, andnot in culturedmyotubes, even though the latter
express the main protein components of the ECC machinery (7).
Epigenetic down-regulation of the ryanodine receptor 1
We focussed the next series of experiments on epigenetic me-
chanisms thatmay be responsible for regulating RyR1 expression
levels and in particular on the content of microRNAs (miRs).
These endogenous ∼22 nucleotide small non-coding RNAs are
known to control gene expression by repressing translation or en-
hancing RNA degradation. Because of the limited amount of bio-
logical material available from patients, we decided to measure
the expression levels of a selected group of muscle-speciﬁc miR
transcripts, namelymiR-1,miR-133,miR-206, and themuscle en-
riched miR-486 (11–13). miR-22 and miR-124 were also measured
as bioinformatics analysis showed that the 3′ UTR of the RYR1
gene contains binding sites for these two miRs. As controls, we
selected miR-126 and miR-221 that are reported to be expressed
in many different tissues (14,15). We analysed muscle biopsies
from 5–9 controls, from 4–5 patients with CCD with dominant
RYR1mutations and from 12–16 patients with mutations leading
to a decrease of RyR1 protein expression with pathological fea-
tures of either MmD or CNM. The latter patients are categorized
as ‘Minicore’, and in addition to muscle weakness, they show
decreased RyR1 protein in their muscle biopsy, and all have the
following common pathological features: several minicores and
increased number of internal nuclei in their muscle biopsy as
well as amyopathic face often accompanied by ophthalmoplegia
(16). All but patients Minicore NL01, UK02, UK05 and UK09 har-
boured recessive RYR1 mutations (see Supplementary Material,
Table S1 for patient’s diagnosis, genotypic and phenotypic charac-
teristics). Figure 2 shows that the relative contents ofmiR-22,miR-
124, miR-1 and miR-133 were reduced to almost undetectable
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levels in biopsies from >60% of Minicore patients with decreased
RyR1 protein expression,whereas the reductionwas not as consist-
ent in biopsies fromCCDpatients. Our results also indicate that the
observed changes in miRs are speciﬁc to some muscle transcripts
andnot causedbyamore globaldefect in themiR-synthesizingma-
chinery, as miR-206, miR486 as well as miR-126 and miR-221 were
not decreased (Fig. 2 and Supplementary Material, Fig. S1).
RYR1methylation
The results obtained so far point to a potential role of regulation
of skeletal muscle gene expression by additional factors.We next
veriﬁed whether changes of DNA methylation occur within the
RYR1 gene. This experiment is essential as methylation-depend-
ent expression of the RYR1 gene was not unexpected considering
the presence of several CpG-rich regions. Genomic DNA was ex-
tracted from biopsies of four controls and four Minicore patients,
and the methylation of CpG regions was studied using the me-
thyl-sensitive HpaII and the methyl-insensitive MspI restriction
enzymes. After cleavage of genomic DNA, quantitative real-
time PCR was performed and compared with a control PCR amp-
lifying a proximal RYR1 gene region lacking HpaII/MspI cleavage
sites (see schematic representation in Fig. 3A). The results
obtained clearly indicate that the CpG-III region of the RYR1
gene (from nucleotide 6790 to nucleotide 7035) of all theMinicore
patients analysed is hypermethylated compared with that of
controls (Fig. 3B) suggesting that RYR1 mutations are associated
withdeep changes in thepatternofDNAmethylation.Additionally,
we analysed biopsies fromMinicore patients and controls for DNA
methyltransferase (DNM) expression and found that in the former
group DNMT1 and DNMT2 are signiﬁcantly up-regulated (Fig. 3C),
whereas the expression of DNMT3 did not vary signiﬁcantly be-
tween controls and patients (results not shown).
HDAC expression levels in muscle biopsies of patients
with minicores with recessive RYR1mutations
The levels of expression of HDAC-4 and HDAC-5 in muscle biop-
sies from controls and patients were subsequently determined
for the following reasons: (i) class II histone deacetylases
(HDACs) can be recruited in association with DNA methylation,
(ii) these enzymes repress transcription by deacetylating core
histones (17), (iii) theyaffectmyogenesis by binding to themuscle
transcription factor mef2 (18), (iv) they are predominantly ex-
pressed in those tissues expressingmef2, that is skeletal muscle,
heart and brain (18) and (v) HDAC-4 is a target of miR-22 whose
down-regulation potentiates HDAC-4 expression (19). Figure 4A
shows a representative western blot of total muscle homogenate
stained with anti-HDAC-4 and HDAC-5 antibodies; the bottom
lane shows a loading control of the same blot stripped and
probedwith anti-myosin heavy chain (MHC) antibodies recogniz-
ing allMHC isoforms. The control biopsyshows low levels of class
II HDACs (Lane 1 Fig. 4A), whereas samples from theMinicore pa-
tients contain abnormally high levels of HDAC-4 and HDAC-5.
Figure 4B shows the relative content of HDAC-4 and HDAC-5
normalized for MHC content in biopsies from all the available
Figure 1. Myotubes from Minicore patients harbouring recessive RYR1 mutations do not show alterations of the resting [Ca2+] nor decreased Ca2+ release after in vitro
stimulation. (A) Fura-2-loaded myotubes were imaged in Krebs Ringer solution containing 2 m Ca2+. No difference in the resting [Ca2+]i was observed between
controls (white bar), cells from patients with recessive mutations (grey bars) or a patient initially diagnosed as MmD carrying the heterozygous p.G297D RYR1
mutation but who also carries two compound heterozygous NEB mutations (black bar). Bars represent the mean (± SEM) ﬂuorescence (340/380 nm) from the indicated
number of cells. (B) KCl-dependent peak Ca2+ release in Krebs Ringer containing 100 µ La3+. Each point represents the mean (±SEM) increase in fura-2 ﬂuorescence
ratio (340/380 nm) of at least 10 myotubes. The data were analysed through Bolzmann equation using Origin 6.0. (C) Western blot analysis of total protein extracts
from muscle biopsies shows major decrease in RyR1 protein expression in Minicore patients. Desmin served as loading control.
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patients. Biopsies from patients with recessive compound het-
erozygous RYR1 mutations, with a non-sense, intronic splice
site or a frameshift mutation in one allele and a missense muta-
tion in the other allele show a 6- to 15-fold increase in class II
HDAC content, and the increase in HDAC-4 expression was also
detectable at the transcriptional level (Fig. 4D). Interestingly,
HDAC-4 was not detectable in any of the myotube cultures
(Fig. 4C) supporting the observed lack of effect of the mutations
on the ECC characteristics of myotubes from the Minicore
patients (Fig. 1). Figure 4E shows a photomicrograph taken by
confocal microscopy on a sample from Minicore SA06; as can be
seen, though thevastmajorityofHDAC-4 isdistributed throughout
the muscle ﬁbre, the amount co-localizing with nuclei is higher in
the patient’s biopsy than in the control biopsy. Analysis of two
Minicore patients and two controls conﬁrmed that the percentage
of HDAC-4 co-localizingwith nuclei is∼10 times higher inmuscles
from Minicore patients than that from controls (9.2 ± 3.8% versus
1.1 ± 0.3%, respectively). We also compared HDAC-4 and HDAC-5
up-regulation and RYR1 hypermethylation in the samples of the
four Minicore patients and found a positive correlation between
high HDAC-4/5 levels and hypermethylation of the studied RYR1
CpG-III gene sequence (Fig. 5A and B).
Effect of HDAC4/5 over-expression and RYR1 silencing
in mouse muscle ﬁbres
To demonstrate a causative link between RYR1mutations and the
above-described epigenetic changes, wemanipulated gene expres-
sion by creating transgenic intact adult mouse skeletal muscle ﬂex-
or digitorum brevis (FDB) ﬁbres by either (i) over-expressing HDAC-4
and HDAC-5 or (ii) knocking down RyR1 by siRNA silencing. When
compared with acute transfection with an empty plasmid, acute
over-expression of HDAC-4 and HDAC-5 directly recapitulates the
effects observed in muscle biopsies from Minicore patients
(Fig. 6). That is, acute over-expression of HDAC-4 and HDAC-5 in
mouse FDB ﬁbres decreases RYR1 transcript expression by ∼70%
(Fig. 6) and RyR1 protein content by 75% (Supplementary Material,
Fig. S3), down-regulates muscle-speciﬁc miRs and down-regulates
the expression of myomesin-1, a muscle-speciﬁc gene whose ex-
pression is regulated by the transcription factor mef2 (20,21)
(Fig. 6). No changes were observed in mef2, miR-126, miR-221 and
miR-486 expression (Supplementary Material, Table S2). On the
other hand, silencing RYR1 for 8 days with siRYR1 signiﬁcantly
increased HDAC-4 and HDAC-5 expression levels but did not
change the expression of muscle-speciﬁc miRs (Fig. 7).
Figure 2. Muscle-speciﬁc miR expression levels differ in biopsies from patients with dominant and recessive RYR1mutations. Each symbol represents the mean relative
expression of the indicated miR from a single patient normalized to RNU44 content and to the muscle-speciﬁc housekeeping genes (DES/ACTN2). Control healthy
individuals, circles; CCD with dominant RYR1 mutations, squares; Minicore, triangles. Statistical analysis was performed using ANOVA and Bonferroni multiple
comparison test (95% conﬁdence interval). miR-22 *P < 0.0005, CTRL n = 9, CCD n = 4, Minicore n = 15; miR-124 **P < 0.05, CTRL and CCD n = 5, Minicore n = 12;
miR-1*P < 0.0005, ***P < 0.009, CTRL n = 8, CCD n = 5, Minicore n = 16; miR133 ****P < 0.002, CTRL n = 10, CCD n = 4, Minicore n = 16; miR-206; no statistical signiﬁcance change
between groups. CTRL n = 9, CCD n = 5, Minicore n = 16. Statistical analysis was performed using ANOVA and Bonferroni multiple comparison test (95% conﬁdence interval).
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Increasing class II HDAC expression does not affect
mef2 expression
Having established that down-regulation of RYR1 causes an in-
crease in HDAC-4/5 expression, we reasoned that this elevation
could lead to downstream effects onmef2, amaster trans-activa-
tor of skeletal muscle gene expression (22). Mef2 is sequestered
by class II HDACs resulting in blockage of mef2-dependent gene
transcription (23), and the RYR1 andmiR-1/miR-133 genes contain
intragenic mef2-dependent enhancer sequences that regulate
their transcription in muscle (24,25). We therefore examined the
patient’s muscle biopsies for: (i) mef2 content, to ascertain that
there was no compensatory up-regulation of its expression
owing to the increased expression of HDAC-4/5 and (ii) myomesin
a protein that is transcriptionally regulated by mef2 (20,21).
Figure 8 shows that the transcript levels of MEF2A, MEF2C and
MEF2D are not signiﬁcantly different between controls and biop-
sies from patients. On the other hand, myomesin-1 protein levels
normalized to MHC are signiﬁcantly decreased (by ∼50% in biop-
sies isolated from patients with minicores (Fig. 8B and C).
HDAC-4/5 are also up-regulated in other congenital
myopathies
To verify whether these observed effects (that is increased levels
of HDACs, decreased levels of RyR1 and decreased levels of mus-
cle-speciﬁcmiRs) are speciﬁc for congenital myopathies owing to
recessive RYR1 mutations or a more general response occurring
in patients with other congenital myopathies, we analysed biop-
sies from 11 patients with NM harbouringmutations in KBTBD13,
ACTA1 or NEB (NEM 6, NEM3 and NEM2, respectively). A similar
decrease in muscle-speciﬁc miR-22, miR-133 and miR-1s was
observed (Supplementary Material, Fig. S2). We also tested the
muscle biopsies from the patients with NM for RyR1 content
and HDAC-4 and HDAC-5 expression. Surprisingly, RyR1 protein
content was signiﬁcantly reduced (control versus NEMwas 100 ±
27.9% versus 0.03 ± 0.02%, P < 0.01, Student’s t-test), and HDAC-4
and HDAC-5 protein levels were signiﬁcantly increased (Supple-
mentary Material, Fig. S2).
Discussion
Here, we identify a novel pathophysiological mechanism occur-
ring in skeletal muscles of patients with congenital myopathies
wherebyactivation of a cascade of events leads to the down-regu-
lation of muscle-speciﬁc genes. We report that recessive com-
pound heterozygous RYR1 mutations are accompanied by the
following changes in skeletal muscle: (i) hypermethylation of
the RYR1 gene, (ii) a 6- to 15-fold increase in class II HDAC expres-
sion and (iii) reduction in muscle-speciﬁc miRs. Our results re-
present a major advancement in the ﬁeld as to date the mode
of action of recessive RYR1 mutations identiﬁed in patients
with MmD, CNM and CFTD has been elusive and the functional
characterization of cells harbouring such mutations has failed
to yield a mechanism compatible with the disease phenotype
(8,10,26). A regular ﬁnding in muscle biopsies of patients with re-
cessive RYR1 mutations has been a reduced expression level of
RyR1 protein and transcript (2–4,26–28). This reduction appears
to be muscle-speciﬁc and has not been observed in other tissues
Figure 3. The RYR1 is hypermethylated, and DNAmethyltransferases 1 and 2 are up-regulated in muscles fromMinicore patients. (A) Schematic representation showing
the location of the CpG region III within the RYR1 gene, the position of the CpG sites (indicated by arrowheads) and the location of the 5′ CCGG 3′HpaII/MspI site (arrowed);
the location of the internal control region lacking HpaII/MspI sites is also shown, aswell as the location of the PCR primers used to amplify the DNA. (B) Hypermethylation
of CpG region III of the RYR1. Each symbol represents the mean relativemethylation value from a patient (CTRL n = 4; Minicore n = 4). Experimental details are outlined in
Materials and Methods. (C) DNA methyltransferase 1 (DNMT1) and DNMT2 are signiﬁcantly up-regulated in muscles of Minicore patients. Each symbol represents the
mean relative expression of DNMT1 (CTRL n = 5; Minicore n = 9) and DNMT2 (CTRL n = 4, Minicore n = 8) from a single patient normalized to the muscle-speciﬁc
housekeeping gene DES (*P < 0.02, **P < 0.025, Student’s t-test).
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ectopically expressing RYR1, such as B-lymphocytes (8). Because
of these results, we set out to test the hypothesis whereby the
mechanism leading to reduced RyR1 muscle expression may be
epigenetically regulated and the schematic representation de-
picted in Figure 9 summarizes the results of the present study.
The key point is that RYR1 mutations are accompanied by an
Figure 4. Class II HDACs are signiﬁcantly up-regulated in muscle biopsies from patients with Congenital Muscle Disorders. (A) Western blot analysis of biopsies from a
control muscle (Lane 1) and Minicore patients (Minicore SA03 and Minicore SA05). Fifty micrograms of total muscle protein extracts were separated on a 6% SDS–PAGE,
blotted onto nitrocellulose and probed with anti-HDAC-4 and HDAC-5 antibodies. Lower portion of the ﬁgure, loading control; the same blot was probed with anti-MHC
recognizing all isoforms. (B) Quantiﬁcation of HDAC-4 and HDAC-5 normalized to MHC in muscle biopsies of controls (circles), CCD patients (squares) and Minicore
patients (triangles). HDAC-4 *P < 0.001, CTRL n = 9, CCD n = 5, Minicore n = 12; HDAC-5**P < 0.01 CTRL, n = 4, CCD n = 3, Minicore n = 9; ANOVA and Bonferroni multiple
comparison test were performed. Each symbol represents results from a single patient. (C) No HDAC-4 protein is detectable in myotubes. (D) HDAC-4 transcript levels
as assessed by qPCR in muscle biopsies from controls and Minicore patients ***P < 0.02, CTRL n = 4, Minicore n = 14; statistical analysis performed using Student t-test.
(E) Confocal microscopy showing distribution of HDAC-4 in a muscle biopsy from a control (left panel) and Minicore patient. Arrows indicate co-localization of HDAC-4
and DAPI. Bar indicates 10 µm.
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increased expression of class II HDACs. We are aware that an in-
crease inHDACexpression has been reported in other conditions,
including denervation, muscle atrophy, ALS and Huntington’s
disease (29–34). However, we would like to point out that (i)
such high levels of expression of class II HDACs have not been re-
ported in any other human neuromuscular abnormalities inves-
tigated so far; (ii) such an increase of HDAC is speciﬁc because the
signal to background ratio of our set of data is 6–16 times greater
than that reported in other muscle disorders and (iii) over-
expression of HDAC-4 and HDAC-5 in mouse FDB ﬁbres results
in the down-regulation of RYR1 and of muscle-speciﬁc miRs.
High levels of HDACs not only lead to chromatin condensation
thereby decreasing gene transcription (21,35,36), but also seques-
ter mef2 (23,37–39). In this context, it should be pointed out that
there is no compensatory up-regulation of mef2 in muscles from
the patients, so that up-regulation of HDACs would lead to the
down-regulation of mef2-dependent proteins. That this is the
case is supported by the fact that RYR1, myomesin and muscle-
speciﬁc miRs containing mef2-dependent binding domains
(21,24,25) are signiﬁcantly down-regulated in the muscles of
Minicore patients. Though few studies have focussed on the me-
chanisms regulating RYR1 expression, the 5′ region of the human
and porcine RYR1 gene contains, aside a mef2-binding domain
(24), consensus sequences for the transcription factor SP1, for
muscle-speciﬁc promoter elements as well as for a number of
transcriptional activators (40). SP1 is a zinc ﬁnger transcription
factor that binds to CG-rich regions present in many promoters.
In ﬁbroblasts, SP1 interacts with HDAC-2 leading to the transcrip-
tional silencing of the human telomerase reverse transcriptase
(hTERT) gene in normal somatic cells (41). Whether SP1 can
also interact with class II HDACs and whether this interaction
is modiﬁed by CpG methylation also leading to repression of
RYR1 gene transcription remains to be investigated.
Interestingly, the 3′ UTR of HDAC-4 and that of HDAC-5 have
binding sites for miR-22/mir-124/miR-1/miR-206 and miR-206,
respectively, and HDAC-4 is a target ofmiR-22 whose down-regu-
lation potentiates its expression (19). Thus, it follows that a de-
crease of miR-22, miR-124 and miR-1 activates a pathological
loop leading to the further up-regulation of class II HDACs
(Fig. 9). This mechanism is compatible with and gives mechanis-
tic insight to two previous observations: (i) other muscle-speciﬁc
genes besides the RYR1 are down-regulated in patients with con-
genital myopathies owing to RYR1mutations (7) and (ii) the RYR1
was reported to be imprinted in some patients with MmD be-
cause of epigenetic factors (42). The former observation is likely
due to the sequestration of mef2 by class II HDACs (37–39). The
latter observations on the other hand can be explained by the
ﬁnding that the DNA methyltransferases DNMT1 and DNMT2
are over-expressed in muscle biopsies of Minicore patients,
bringing about RYR1hypermethylation. DNMT1 is amaintenance
methyltransferases preservingmethylation patterns but also has
de novo activity (43). DNMT2 on the other hand is thought to par-
ticipate in the recognition of damaged DNA and mutation repair
(44). In fact, the two observations are mechanistically linked as
hypermethylation goes hand in hand with HDAC activation and
gene down-regulation (23,24,35,36,45); furthermore, DNA dam-
age can activate DNA-methylation via activation of DNMT1 (46),
resulting in a pathological loop that will ultimately shut down
gene transcription of mef2-dependent genes.
As to the role miRs in neuromuscular diseases, this is still un-
clear: over-expression ofmiR-22 is sufﬁcient to cause cardiomyo-
cyte hypertrophy (47) and several miRs are up-regulated in
muscular dystrophies (48–50) but depending on the disease,
some miRs may appear to be down-regulated (50). Interestingly,
a recent study demonstrated that mice lacking miR-133 develop
an adult onset CNM in type-2 ﬁbres, and this is accompanied by
impaired mitochondrial function, fast to slow myoﬁber conver-
sion and disarrangement of triads (51), histopathological
changes very similar to those observed in recessive human
RYR1-related myopathies. Though in the paper the authors con-
clude that this is principally due to the dysregulation of dyna-
min-2, one of miR-133′s targets, the similarities between the
phenotype of the miR-133a knockout mice and that of patients
with RYR1 mutations is striking and is indicative of a common
pathophysiological pathway.
The main point emerging from our studies is that epigenetic
factors are central culprits in recessive RYR1-linked myopathies.
Our results also show that these factors are likely to also play a
major role in other congenital muscle diseases such as NM. In
support of a role of epigenetics, moderate exercise has been
shown to improve the muscle function of some patients with
congenital myopathies (52,53) and there is increasing evidence
that physical activity inﬂuences DNA methylation in humans
(53,54). Taken together our results suggest that a common patho-
physiological mechanism is activated in skeletal muscles of
patients with some congenital myopathies. The presence of
mutations in muscle-speciﬁc genes (in this case RYR1) activates
factors that lead to the up-regulation of DNMs and of class II
HDACs, the master regulator of chromatin structure. Though
the primary mechanism causing HDAC up-regulation is at the
moment unclear, our data provide the proof of concept that
Figure 5. Correlation between DNA methylation and HDAC-4/HDAC-5 expression
and up-regulation of DNA methyltransferases in muscles of patients with
Minicore. The data shown in this ﬁgures were obtained from biopsies from four
control individuals (empty squares) and from biopsies from four Minicore patients
(ﬁlled squares) (Minicore NL02, Minicore NL03; Minicore SA03, Minicore SA05).
(A) Correlation between HDAC-4 and RYR1 hypermethylation (correlation
coefﬁcient r = 0.4695). (B) Correlation between HDAC-5 and RYR1 hypermethylation
(correlation coefﬁcient r = 0.7925).
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DNM and HDAC are potential pharmacological targets to treat a
wide range of inherited neuromuscular conditions with different
genetic backgrounds that as a common feature lead to a decrease
in RyR1.
Materials and Methods
Quantitative PCR
Total RNA was extracted using Trizol (Life Technologies,
#15596018). cDNAwas synthesized with the High Capacity cDNA
synthesis kit or Taqman microRNA Reverse Transcription kit
(Applied Biosystems, #4366596). Transcript levels were quantiﬁed
using Syber-Green reagent on an Applied Biosystem platform
(7500 fast real-time PCR system); levels of expression from tripli-
cate replicas were averaged and normalized to the content of the
muscle-speciﬁc gene desmin (DES). In the case of human samples,
because of the limited amount of biological material, not all biop-
sies could be investigated for all genes. The sequences of the pri-
mers used for qPCR are listed in SupplementaryMaterial, Table S3.
MicroRNA determination
Quantiﬁcation of selected miRs was performed using TaqMan
master mix no-UNG 2 (Life Technologies, # PN 4427788) and the
following miR assays (Life Technologies, # PN 4427975): miR-22,
miR124a, miR-133a, miR-1, miR-206, miR-486-3p, miR-221 and
miR-126. Each reaction was performed in triplicate, and the re-
sults from each muscle sample were analysed and averaged. In
human muscle biopsies, miR expression levels were normalized
to RNU44 and to the muscle-speciﬁc genes DES and Actinin2
(ACTN2) that show similar Ct values in patients and healthy indi-
viduals. In mouse FDBs, miR expression levels were normalized
to U6 snRNA. In the case of human samples, because of the
limited amount of biological material, not all biopsies could be
investigated for all microRNAs.
DNA methylation
Total genomic DNAwas isolated using the GeneElutemammalian
genomic DNA Miniprep kit (Sigma Genosys). DNA methylation
Figure 6. In vivo over-expression of HDAC-4 and HDAC-5 causes down-regulation of RYR1 and of muscle-speciﬁc miRs. Each symbol shows the mean triplicate relative
expression value of the indicated transcript normalized to the indicated gene. Circles, control FDB ﬁbres mock transfected with the empty pIRES2-dsRed2 plasmid;
squares, FDB ﬁbres transfected with a plasmid encoding mouse HDAC-4 and HDAC-5. HDAC-4; *P < 0.0001, n = 6; HDAC-5 **P < 0.005, n = 6; RYR1 **P < 0.005, CTRL n = 4,
HDAC-4 and 5 n = 6; miR-22 and miR-1; ***P < 0.045, n = 6; miR-133 ****P < 0.035, n = 6; miR-206 ****P < 0.035, n = 5; Myomesin ****P < 0.035, n = 4; miR-124 was quantiﬁed and
no signiﬁcance change was observed. Statistical analysis was performed using the Student’s t-test.
Human Molecular Genetics, 2015, Vol. 24, No. 16 | 4643
was assessed by PCR ampliﬁcation of genomic DNA digested with
the methyl-sensitive HpaII and MspI restriction enzymes (55)
(see schematic representation in Fig. 3A). Restriction enzyme
digestion reactions were carried out overnight at 37°C, with
HpaII or MspI (New England BioLabs), in ﬁnal volume of 20 µl.
The primers used for PCR ampliﬁcation are listed in Supple-
mentary Material, Table S3 as: Human RYR1 CG-rich (F and R)
amplifying the CpG-III region of the RYR1 gene and Human
RYR1 Control (F and R), amplifying a control region of the
RYR1 gene lacking HpaII/MspI sites (see Fig. 3A). To determine
the extent of DNA methylation, the ΔCt values were ﬁrst ob-
tained comparing the CpG-III and control PCRs of HpaII diges-
tions, and then the ΔΔCt values were generated using as
reference the samples exhibiting the higher ΔCt. Higher ΔΔCt
values indicate higher extent of DNA methylation at the CpG-
III RyR1 MspI/HpaII cleavage sites.
Figure 7. Down-regulation of RYR1 by siRNA leads to up-regulation of HDAC-4 and HDAC-5. Each symbol shows the mean triplicate value relative expression level of the
indicated transcript normalized to U6 snRNA (miR expression) or DES (RYR and HDAC expression), in ﬁbres isolated from a single mouse. Circles, control (mock)
transfection with a scrambled siRNA; squares FDB transfected with siRYR RNA (see Materials and Methods for details). RYR1 *P < 0.0001, n = 7; HDAC-4 **P < 0.04, CTRL
n = 6, siRYR1 n = 7. HDAC-5; **P < 0.04, CTRL n = 6, siRYR1 n = 9. miR-22, miR-133, miR-124 and miR-1 show no statistical difference. Statistical analysis was performed
using the Student’s t-test.
Figure 8. Increased expression of HDAC-4/HDAC-5 leads to a decrease in the content of myomesin, without affectingmef2. (A) mef2A, mef2C andmef2D transcript levels
are similar in muscle biopsies of patients and controls (expression levels normalized to DES). (B) Representative western blot showing that the protein content of
myomesin is lower in patients with Minicore compared with healthy individuals (letters and numbers refer to patient no.; see Supplementary Material, Table S1);
(C). Quantiﬁcation of myomesin protein content in muscle biopsies: controls, circles (n = 6); CCD, squares (n = 5); Minicore, triangles (n = 9). *P < 0.02. Statistical analysis
was performed using ANOVA and Bonferroni multiple comparison test (95% conﬁdence interval).
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Electrophoresis and immunoblotting
Totalmuscleproteinswereextracted in10mHepespH7.0, 150m
NaCl, 1 m EDTA and anti-protease (Roche, # 11873580001). Pro-
tein concentration was determined using Protein Assay Kit II
(Bio-Rad Laboratories) using BSA as a standard. SDS–PAGE, pro-
tein transfer on to nitrocellulose membranes and immunostain-
ing were performed as described previously (2,8). The following
primary antibodies were used:mouse anti-RyR1 (Ryanodine 1 Re-
ceptor, Thermo Scientiﬁc, # MA3-925), mouse anti-MHC (MHC,
Millipore, #05-716), Rabbit anti-HDAC-4 (Histone Deacetylase 4,
Cell Signaling, #2072) and rabbit anti- HDAC-5 (Histone Deacety-
lase 5, Abcam #1439), and rat anti-myomesin was a generous
gift of Prof. Mathias Gautel, King’s College, London, UK (56). Sec-
ondary peroxidase conjugateswere Protein G–peroxidase (Sigma,
#P8170) and peroxidase-conjugated goat anti-mouse IgG (Sigma,
#A2304). The immunopositive bandswere visualized by chemilu-
minescence using the Super SignalWest Dura kit (Thermo Scien-
tiﬁc). In order to perform statistical analysis, the intensity of the
immunopositive bands was determined using ImageJ/FIJI. The
intensity valueswere normalized to the intensity of the indicated
muscle-speciﬁc housekeeping protein. The value (arbitrary units)
obtained from the patient’s biopsies were divided by the mean
value obtained from control biopsies and are expressed as 100%.
Mouse muscle ﬁbre electroporation and isolation
The procedurewas as described byDiFranco et al. (57). Brieﬂy, 8- to
14-week-oldmicewere anaesthetizedusing isoﬂuorane, and 7.5 µl
of 2 mg/ml Hyaluronidase in RNase-free Tyroide’s Buffer (Sigma
Fine Chemicals, #H3506) was injected under the footpad. The
mice were left 1 h under supervision, and subsequently, the fol-
lowing constructs were injected into the footpad: pCMV6-HDAC4
(Origene #MR211598) and pCMV6-HDAC5 (Origene # MC202550)
whereas control mice (mock transfected) received 20 µg of
pIRES2-dsRed2 plasmid (Clonetech #632420). For siRNA silencing
experiments, 6 nmol of RNA either speciﬁc for the RYR1 (Ambion;
siRNA RyR1-#4390771) or a scrambled siRNA sequence (Negative
control 2-#4390845) were used. siRNA-transfected FDBs were also
injected with lipofectamine RNAiMAX (Invitrogen, #13778-030).
Ten minutes post-injection, FDBs were electroporated using
acupuncture needles placed parallel and perpendicular to the
long axis of the foot (with 1 cm distance), and twenty pulses
(100v/cm, 20 ms duration and 1 Hz of frequency) were given. Six
to ten days post–transfection, the mice were sacriﬁced and FDBs
were isolated by enzymatic dissociation at 37°C for 60 min in
Krebs Ringer solution no Ca2+ (pH 7.4), containing 0.2% collage-
nase I (Sigma Fine Chemicals, C-0130). Enzymatic digestion was
terminated by washing the muscle with Tyrode’s solution (pH
7.4), and single ﬁbres were isolated and total protein extracts
prepared or RNAwas extracted and analysed by qPCR.
Ca2+ measurements
Primary skeletal muscle cultures and cell imaging were per-
formed as previously described (58).
Confocal microscopy and immunoﬂuorescence
Biopsies were embedded for pathological examination and sliced
using a cryostat (10 µm thickness). Cryosections were ﬁxed with
methanol: acetone (1:1) for 30 min and then incubated in the fol-
lowing solutions for 90 min at room temperature: blocking solu-
tion (Roche, #115000694011), rabbit anti-HDAC-4 (Cell Signaling,
#2072) andAlexa Fluor 647-conjugated anti-Rabbit IgG (Life Tech-
nologies, #A21245). Nuclear staining was performed using DAPI
(Invitrogen, #D21490), and slides were mounted with mounting
medium (Sigma, #1000-4) and sealed hermetically with 1.5-
mm-thick coverslip. A Nikon A1R Confocal microscope was
used for 3D image acquisition with a 40× oil objective (N.A. = 1.3).
Imageswere analysed using threshold co-localization function in
ImageJ2/FIJI program.
Compliance with ethical standards
All procedures performed in studies involving human partici-
pants were in accordance with the ethical standards of the insti-
tutional and/or national research committee and with the 1964
Helsinki declaration and its later amendments or comparable
ethical standards. This study was approved by the Ethikkommis-
sion beider Basel (permit No. EK64/12); all subjects gave written
informed consent to carry out this work.
All applicable international, national and/or institutional
guidelines for the care and use of animals were followed. All pro-
cedures performed in studies involving animals were in accord-
ance with the ethical standards of the institution or practice at
which the studies were conducted. Experiments on mouse mus-
cles were approved by the local Cantonal Veterinary authorities
(permit No. 2658).
Statistical analysis and graphical software
Statistical analysis was performed using the Student’s t-test;
means were considered statistically signiﬁcant when the
P-value was < 0.05. When more than two groups were compared,
analysis was performed using the ANOVA test followed by the
Bonferroni post hoc test using the statistical package included in
GraphPad Prism 6.0 software. Origin 6 was used to generate
dose–response curves. Images were assembled using Adobe
Photoshop CS (version 8.0).
Supplementary Material
Supplementary Material is available at HMG online.
Figure 9. Cartoon depicting how mutations in RYR1 lead to a decrease in
RyR1 content thereby leading to weak muscles. Mutations lead to DNA
hypermethylation and HDAC-4/HDAC-5 over-expression. This causes mef2
sequestration thereby inhibiting transcription of genes regulated by mef2,
including the RYR1 and muscle-speciﬁc miRs. A decrease in RyR1 would
severely affect muscle excitation–contraction coupling because this calcium
channel is a central player in this mechanism, releasing the calcium necessary
for muscle contraction from the sarcoplasmic reticulum.
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